T cell vaccines for microbial infections

Nature Medicine

Volumn 11, Issue 4S, 2005, Pages S25-

  Robinson, Harriet L ^a   Amara, Rama Rao ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BACTERIAL INFECTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; T-LYMPHOCYTES; VACCINES; VIRUS DISEASES;

BCG VACCINE; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD27 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CCR7; DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 7; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MALARIA VACCINE; PERFORIN; PROTEIN BCL 2; SMALLPOX VACCINE; TUMOR NECROSIS FACTOR; VIRUS VECTOR;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; CANARYPOX VIRUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MACACA; MALARIA; MEMORY CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CELL; POXVIRUS; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; SUPPRESSOR CELL; SYSTEMATIC REVIEW; T LYMPHOCYTE; TUBERCULOSIS; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; CANARYPOX VIRUS; CHORIOMENINGITIS VIRUS; HUMAN ADENOVIRUS TYPE 5; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MACACA; MYCOBACTERIUM BOVIS BCG; POXVIRIDAE; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 17644419950     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1212     Document Type: Article

References (92)

1. Nossal, G.J. The Global Alliance for Vaccines and Immunization-a millennial challenge. Nat. Immunol. 1, 5-8 (2000).
2. Burton, D.R. et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5, 233-236 (2004).
3. Robinson, H.L. New Hope for an AIDS Vaccine. Nat. Rev. Immunol. 2, 239-250 (2002).
4. Letvin, N.L. Progress toward an HIV vaccine. Annu. Rev. Med. 56, 213-223 (2005).
5. Bourgeois, C., Rocha, B. & Tanchot, C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297, 2060-2063 (2002).
6. Janssen, E.M. et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421, 852-856 (2003).
7. Shedlock, D.J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337-339 (2003).
8. Sun, J.C. & Bevan, M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339-342 (2003).
9. Sun, J.C., Williams, M.A. & Bevan, M.J. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol. 5, 927-933 (2004).
10. Borrow, P. et al. CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J. Exp. Med. 183, 2129-2142 (1996).
11. Rubbert, A. et al. Multifactorial nature of noncytolytic CD8+ T cell-mediated suppression of HIV replication: Beta-chemokine-dependent and -independent effects. AIDS Res. Hum. Retroviruses 13, 63-69 (1997).
12. Levy, J.A., Mackewicz, C.E. & Barker, E. Controlling HIV pathogenesis: The role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol. Today 17, 217-224 (1996).
13. Pal, R. et al. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 278, 695-698 (1997).
14. Amara, R.R. et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76, 6138-6146 (2002).
15. Amara, R.R. et al. Different patterns of immune responses but similar control of a mucosal immunodeficiency virus challenge by MVA and DNA/MVA vaccines. J. Virol. 76, 7625-7631 (2002).
16. Smith, J.M. et al. Multiprotein HIV-1 Clade B DNA/MVA Vaccine: Construction, Safety and Immunogenicity. AIDS Res. Hum. Retroviruses 20, 654-665 (2004).
17. Smith, J.M. et al. DNA/MVA vaccine for HIV type 1: Effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res. Hum. Retroviruses 20, 1335-1347 (2004).
18. Sette, A. & Fikes, J. Epitope-based vaccines: An update on epitope identification, vaccine design and delivery. Curr. Opin. Immunol. 15, 461-470 (2003).
19. Goulder, P.J. & Watkins, D.I. HIV and SIV CTL escape: Implications for vaccine design. Nat. Rev. Immunol. 4, 630-640 (2004).
20. Lechner, F. et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191, 1499-1512 (2000).
21. Wherry, E.J., Blattman, J.N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911-4927 (2003).
22. Kostense, S. et al. Persistent numbers of tetramer+ CD8(+) T cells, but loss of inter- feron-gamma+ HIV-specific T cells during progression to AIDS. Blood 99, 2505-2511 (2002).
23. Sadagopal, S. et al. Signature for Long-term vaccine-mediated controlof as SHIV-98.6P challenge: Stable low breadth and low frequency T cell response capable of co-producing IFN-gamma and IL-2. J. Virol. 79, 3243-3253 (2005).
24. McKay, P.F. et al. Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys. J. Immunol. 168, 332-337 (2002).
25. Migueles, S.A. et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3, 1061-1068 (2002).
26. Kaech, S.M., Wherry, E.J. & Ahmed, R. Effector and memory T-cell differentiation: Implications for vaccine development. Nat. Rev. Immunol. 2, 251-262 (2002).
27. Welsh, R.M., Selin, L.K. & Szomolanyi-Tsuda, E. Immunological memory to viral infections. Annu. Rev. Immunol. 22, 711-743 (2004).
28. Ahmed, R. & Gray, D. Immunological memory and protective immunity: Understanding their relation. Science 272, 54-60 (1996).
29. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
30. Grayson, J.M., Harrington, L.E., Lanier, J.G., Wherry, E.J. & Ahmed, R. Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo. J. Immunol. 169, 3760-3770 (2002).
31. Badovinac, V.P., Messingham, K.A., Hamilton, S.E. & Harty, J.T. Regulation of CD8+ T cells undergoing primary and secondary responses to infection in the same host. J. Immunol. 170, 4933-4942 (2003).
32. Amara, R.R., Nigam, P., Sharma, S., Liu, J. & Bostik, V. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J. Virol. 78, 3811-3816 (2004).
33. Hammarlund, E. et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9, 1131-1137 (2003).
34. Crotty, S. etal. Cutting edge: Long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171, 4969-4973 (2003).
35. Demkowicz, W.E., Jr., Littaua, R.A., Wang, J. & Ennis, F.A. Human cytotoxic T-cell memory: Long-lived responses to vaccinia virus. J. Virol. 70, 2627-2631 (1996).
36. Wherry, E.J., Puorro, K.A., Porgador, A. & Eisenlohr, L.C. The induction of virus-specific CTL as a function of increasing epitope expression: Responses rise steadily until excessively high levels of epitope are attained. J. Immunol. 163, 3735-3745 (1999).
37. Pardigon, N. et al. Role of co-stimulation in CD8+ T cell activation. Int. Immunol. 10, 619-630 (1998).
38. Whitmire, J.K. & Ahmed, R. Costimulation in antiviral immunity: Differential requirements for CD4(+) and CD8(+) T cell responses. Curr. Opin. Immunol. 12, 448-455 (2000).
39. Marrack, P. & Kappler, J. Control of T cell viability. Annu. Rev. Immunol. 22, 765-787 (2004).
40. Blattman, J.N. et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9, 540-547 (2003).
41. Yajima, T. et al. Overexpression of IL-15 in vivo increases antigen-driven memory CD8+ T cells following a microbe exposure. J. Immunol. 168, 1198-1203 (2002).
42. Khan, I.A. & Casciotti, L. IL-15 prolongs the duration of CD8+ T cell-mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii. J. Immunol. 163, 4503-4509 (1999).
43. Sprent, J., Zhang, X., Sun, S. & Tough, D. T-cell proliferation in vivo and the role of cytokines. Philos. Trans. R. Soc. Lond. B Biol. Sci. 355, 317-322 (2000).
44. Badovinac, V.P., Tvinnereim, A.R. & Harty, J.T. Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 290, 1354-1358 (2000).
45. Kagi, D., Odermatt, B. & Mak, T.W. Homeostatic regulation of CD8+ T cells by perforin. Eur. J. Immunol. 29, 3262-3272 (1999).
46. Matloubian, M. et al. A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol 73, 2527-36 (1999).
47. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712 (1999).
48. Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: Function, generation, and maintenance. Annu. Rev. Immunol. 22, 745-763 (2004).
49. Appay, V. et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8, 379-385 (2002).
50. Ravkov, E.V., Myrick, C.M. & Altman, J.D. Immediate early effector functions of virus- specific CD8+CCR7+ memory cells in humans defined by HLA and CC chemokine ligand 19 tetramers. J. Immunol. 170, 2461-2468 (2003).
51. Geginat, J., Lanzavecchia, A. & Sallusto, F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101, 4260-4266 (2003).
52. Faint, J.M. et al. Memory T cells constitute a subset of the human CD8+CD45RA+ pool with distinct phenotypic and migratory characteristics. J. Immunol. 167, 212-220 (2001).
53. van Leeuwen, E.M. et al. Proliferation requirements of cytomegalovirus-specific, effector-type human CD8+ T cells. J. Immunol. 169, 5838-5843 (2002).
54. Champagne, P. et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106-111 (2001).
55. Wherry, E.J. et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4, 225-234 (2003).
56. Prlic, M., Lefrancois, L. & Jameson, S.C. Multiple choices: Regulation of memory CD8 T cell generation and homeostasis by interleukin (IL)-7 and IL-15. J. Exp. Med. 195, F49-F52 (2002).
57. Tan, J.T. et al. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. 195, 1523-1532 (2002).
58. Pulendran, B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 199, 227-250 (2004).
59. Schneider, J. et al. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. Immunol. Rev. 170, 29-38 (1999).
60. Robinson, H.L., Smith, J.M. & Amara, R.R. AIDS Vaccines: Heterologous Prime/Boost Strategies for raising Protective T Cell Responses. AIDS Rev. 2, 105-110 (2000).
61. Sumida, S.M. et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78, 2666-2673 (2004).
62. Shiver, J.W. & Emini, E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355-372 (2004).
63. Reyes-Sandoval, A. et al. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J. Virol. 78, 7392-7399 (2004).
64. Yang, Z.Y. et al. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77, 799-803 (2003).
65. Allen, T.M. et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA Prime/Modified vaccinia virus ankara boost regimen. J. Immunol. 164, 4968-4978 (2000).
66. Reimann, K.A. et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70, 6922-6928 (1996).
67. Barouch, D.H. et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol. 161, 1875-1882 (1998).
68. Santra, S. et al. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc. Natl. Acad. Sci. USA 101, 11088-11093 (2004).
69. Appay, V. et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192, 63-75 (2000).
70. Gruener, N.H. et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J. Virol. 75, 5550-5558 (2001).
71. Barouch, D.H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335-339 (2002).
72. Kahn, P. AIDS Vaccines, From Monkeys to People: An Interview with John Shriver. in IAVI Report Vol. 7 10-12 (International AIDS Vaccine Initiative, New York, 2003).
73. Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
74. Waldrop, S.L., Pitcher, C.J., Peterson, D.M., Maino, V.C. & Picker, L.J. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J. Clin. Invest. 99, 1739-1750 (1997).
75. Waldrop, S.L., Davis, K.A., Maino, V.C. & Picker, L.J. Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J. Immunol. 161, 5284-5295 (1998).
76. Lyons, A.B. & Parish, C.R. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171, 131-137 (1994).
77. De Rosa, S.C. et al. Vaccination in humans generates broad T cell cytokine responses. J. Immunol. 173, 5372-5380 (2004).
78. MacGregor, R.R. et al. First human trial of a facilitated DNA plasmid vaccine for HIV-1: Safety and host response. in Int. Conf. AIDS 11, 23 (abstract no. We.B.293) (1996).
79. MacGregor, R.R. et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J. Infect. Dis. 178, 92-100 (1998).
80. Moorthy, V.S. et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 21, 1995-2002 (2003).
81. Moorthy, V.S. et al. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. J. Infect. Dis. 188, 1239-1244 (2003).
82. McConkey, S.J. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccine virus Ankara in humans. Nat. Med. 9, 729-735 (2003).
83. Moorthy, V.S. et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis. 189, 2213-2219 (2004).
84. Moore, A.C. & Hill, A.V. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunol. Rev. 199, 126-143 (2004).
85. McShane, H. et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10, 1240-1244 (2004).
86. Lai, C.J. & Monath, T.P. Chimeric flaviviruses: Novel vaccines against dengue fever, tickborne encephalitis, and Japanese encephalitis. Adv. Virus Res. 61, 469-509 (2003).
87. Kaech, S.M. & Ahmed, R. Memory CD8+ T cell differentiation: Initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2, 415-422 (2001).
88. Wyand, M.S., Manson, K.H., Garcia-Moll, M., Montefiori, D. & Desrosiers, R.C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70, 3724-3733 (1996).
89. Amara, R.R. et al. Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine. Science 292, 69-74 (2001).
90. Shiver, J.W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 415, 331-335 (2002).
91. Barouch, D.H. et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. USA 97, 4192-4197 (2000).
92. Barouch, D.H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).